Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical Inks Distribution Deal with Fisher HealthCare

NEW YORK (GenomeWeb News) – Response Biomedical today said that it has signed a new, nonexclusive deal for Fisher HealthCare to distribute its portfolio of infectious disease tests in the US.

Fisher HealthCare, which is part of Thermo Fisher Scientific, will distribute Response Bio's Infectious Disease Point of Care test panel, which includes the Ramp Flu A + B test and the Ramp RSV test. The assays run on the firm's Ramp 200 system.

"This is a key strategic agreement for Response as we continue our investment into the US marketplace for POC testing," Tim Shannon, SVP of worldwide sales and marketing for Response Biomedical, said in a statement. "The knowledge and experience of Fisher HealthCare in this market is a vital part of our strategy to substantially increase our penetration into this highly competitive region."

Earlier this month, Vancouver, British Columbia-based Response Bio signed a US distribution deal with Labsco covering its cardiovascular portfolio of Ramp products.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.